Energy Expenditure Evaluation in Humans and Non-Human Primates by SenseWear Armband : Validation of Energy Expenditure Evaluation by SenseWear Armband by Direct Comparison with Indirect Calorimetry

Introduction:The purpose of this study was to compare and validate the use of SenseWear Armband (SWA) placed on the arm (SWA ARM) and on the back (SWA BACK) in healthy humans during resting and a cycle-ergometer exercise and to evaluate the SWA to estimate Resting Energy Expenditure (REE) and Total Energy Expenditure (TEE) in healthy baboons.Methods:We studied 26 (15F/11M) human subjects wearing SWA in two different anatomical sites (arm and back) during resting and a cycle-ergometer test and directly compared these results with indirect calorimetry evaluation (IC), performed at the same time. We then inserted the SWA in a metabolic jacket for baboons and evaluated the TEE and REE in free living condition for 6 days in 21 (8F/13M) non-human primates.Results:In humans we found a good correlation between SWA place on the ARM and on the BACK with IC during the resting experiment (1.1\ub10.3 SWAs, 1\ub10.2 IC kcal/min) and a slight underestimation in the SWAs data compared with IC during the cycle-ergometer exercise (5\ub11.9 SWA ARM, 4.5\ub11.5 SWA BACK and 5.4\ub12.1 IC kcal/min). In the non-human primate (baboons) experiment SWA estimated a TEE of 0.54\ub10.009 kcal/min during free living and a REE of 0.82\ub10.06 kcal/min.Conclusion:SWA, an extremely simple and inexpensive apparatus, provides quite accurate measurements of energy expenditure in humans and in baboons. Energy expenditure data obtained with SWA are highly correlated with the data obtained with "gold standard", IC, in humans. \ua9 2013 Casiraghi et al

Duodenal adipose tissue is associated with obesity in baboons (Papio sp) : a novel site of ectopic fat deposition in non-human primates

AimsEctopic fat is a recognized contributor to insulin resistance and metabolic dysfunction, while the role of fat deposition inside intestinal wall tissue remains understudied. We undertook this study to directly quantify and localize intramural fat deposition in duodenal tissue and determine its association with adiposity.MethodsDuodenal tissues were collected from aged (21.21.3years, 19.53.1kg, n=39) female baboons (Papio sp.). Fasted blood was collected for metabolic profiling and abdominal circumference (AC) measurements were taken. Primary tissue samples were collected at the major duodenal papilla at necropsy: one full cross section was processed for hematoxylin and eosin staining and evaluated; a second full cross section was processed for direct chemical lipid analysis on which percentage duodenal fat content was calculated.Results Duodenal fat content obtained by direct tissue quantification showed considerable variability (11.95 +/- 6.93%) and was correlated with AC (r=0.60, p<0.001), weight (r=0.38, p=0.02), leptin (r=0.63, p<0.001), adiponectin (r=-0.32, p<0.05), and triglyceride (r=0.41, p=0.01). The relationship between duodenal fat content and leptin remained after adjusting for body weight and abdominal circumference. Intramural adipocytes were found in duodenal sections from all animals and were localized to the submucosa. Consistent with the variation in tissue fat content, the submucosal adipocytes were non-uniformly distributed in clusters of varying size. Duodenal adipocytes were larger in obese vs. lean animals (106.9 vs. 66.7 mu m(2), p=0.02).Conclusions Fat accumulation inside the duodenal wall is strongly associated with adiposity and adiposity related circulating biomarkers in baboons. Duodenal tissue fat represents a novel and potentially metabolically active site of ectopic fat deposition

Exenatide regulates pancreatic islet integrity and insulin sensitivity in the nonhuman primate baboon Papio hamadryas.

The glucagon-like peptide-1 receptor agonist exenatide improves glycemic control by several and not completely understood mechanisms. Herein, we examined the effects of chronic intravenous exenatide infusion on insulin sensitivity, β cell and α cell function and relative volumes, and islet cell apoptosis and replication in nondiabetic nonhuman primates (baboons). At baseline, baboons received a 2-step hyperglycemic clamp followed by an l-arginine bolus (HC/A). After HC/A, baboons underwent a partial pancreatectomy (tail removal) and received a continuous exenatide (n = 12) or saline (n = 12) infusion for 13 weeks. At the end of treatment, HC/A was repeated, and the remnant pancreas (head-body) was harvested. Insulin sensitivity increased dramatically after exenatide treatment and was accompanied by a decrease in insulin and C-peptide secretion, while the insulin secretion/insulin resistance (disposition) index increased by about 2-fold. β, α, and δ cell relative volumes in exenatide-treated baboons were significantly increased compared with saline-treated controls, primarily as the result of increased islet cell replication. Features of cellular stress and secretory dysfunction were present in islets of saline-treated baboons and absent in islets of exenatide-treated baboons. In conclusion, chronic administration of exenatide exerts proliferative and cytoprotective effects on β, α, and δ cells and produces a robust increase in insulin sensitivity in nonhuman primates

Central GIP signaling stimulates peripheral GIP release and promotes insulin and pancreatic polypeptide secretion in nonhuman primates

Glucosedependent insulinotropic polypeptide (GIP) has important actions on whole body metabolic function. GIP and its receptor are also present in the central nervous system and have been linked to neurotrophic actions. Metabolic effects of central nervous system GIP signaling have not been reported. We investigated whether centrally administered GIP could increase peripheral plasma GIP concentrations and influence the metabolic response to a mixed macronutrient meal in nonhuman primates. An infusion and sampling system was developed to enable continuous intracerebroventricular (ICV) infusions with serial venous sampling in conscious nonhuman primates. Male baboons (Papio sp.) that were healthy and had normal body weights (28.9 \ub1 2.1 kg) were studied (n = 3). Animals were randomized to receive continuous ICV infusions of GIP (20 pmol\ub7kg-1\ub7h-1) or vehicle before and over the course of a 300-min mixed meal test (15 kcal/kg, 1.5g glucose/kg) on two occasions. A significant increase in plasma GIP concentration was observed under ICV GIP infusion (66.5 \ub1 8.0 vs. 680.6 \ub1 412.8 pg/ml, P = 0.04) before administration of the mixed meal. Increases in postprandial, but not fasted, insulin (P = 0.01) and pancreatic polypeptide (P = 0.04) were also observed under ICV GIP. Effects of ICV GIP on fasted or postprandial glucagon, glucose, triglyceride, and free fatty acids were not observed. Our data demonstrate that central GIP signaling can promote increased plasma GIP concentrations independent of nutrient stimulation and increase insulin and pancreatic polypeptide responses to a mixed meal

Physiological and molecular determinants of insulin action in the baboon

OBJECTIVE-To quantitate insulin sensitivity in lean and obese nondiabetic baboons and examine the underlying cellular/ molecular mechanisms responsible for impaired insulin action to characterize a baboon model of insulin resistance. RESEARCH DESIGN AND METHODS-Twenty baboons received a hyperinsulinemic-euglycemic clamp with skeletal muscle and visceral adipose tissue biopsies at baseline and at 30 and 120 min after insulin. Genes and protein expression of key molecules involved in the insulin signaling cascade (insulin receptor, insulin receptor substrate-1, p85, phosphatidylinositol 3-kinase, Akt, and AS160) were sequenced, and insulin-mediated changes were analyzed. RESULTS-Overall, baboons show a wide range of insulin sensitivity (6.2 \ub1 4.8 mg \ub7 kg -1 \ub7 min -1), and there is a strong inverse correlation between indexes of adiposity and insulin sensitivity (r =-0.946, P < 0.001 for % body fat; r =-0.72, P < 0.001 for waist circumference). The genes and protein sequences analyzed were found to have 3c 98% identity to those of man. Insulin-mediated changes in key signaling molecules were impaired both in muscle and adipose tissue in obese insulin-resistant compared with lean insulin-sensitive baboons. CONCLUSIONS-The obese baboon is a pertinent nonhuman primate model to examine the underlying cellular/molecular mechanisms responsible for insulin resistance and eventual development of type 2 diabetes

Feto-placental Adaptations to Maternal Obesity in the Baboon

Photograph of a scene with 89er reenactors at Fort Reno

Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates

In this study, we aimed to evaluate the effects of exenatide (EXE) treatment on exocrine pancreas of nonhuman primates. To this end, 52 baboons (Papio hamadryas) underwent partial pancreatectomy, followed by continuous infusion of EXE or saline (SAL) for 14 weeks. Histological analysis, immunohistochemistry, Computer Assisted Stereology Toolbox morphometry, and immunofluorescence staining were performed at baseline and after treatment. The EXE treatment did not induce pancreatitis, parenchymal or periductal inflammatory cell accumulation, ductal hyperplasia, or dysplastic lesions/pancreatic intraepithelial neoplasia. At study end, Ki-67-positive (proliferating) acinar cell number did not change, compared with baseline, in either group. Ki-67-positive ductal cells increased after EXE treatment (P = 0.04). However, the change in Ki-67-positive ductal cell number did not differ significantly between the EXE and SAL groups (P = 0.13). M-30-positive (apoptotic) acinar and ductal cell number did not change after SAL or EXE treatment. No changes in ductal density and volume were observed after EXE or SAL. Interestingly, by triple-immunofluorescence staining, we detected c-kit (a marker of cell transdifferentiation) positive ductal cells co-expressing insulin in ducts only in the EXE group at study end, suggesting that EXE may promote the differentiation of ductal cells toward a \u3b2-cell phenotype. In conclusion, 14 weeks of EXE treatment did not exert any negative effect on exocrine pancreas, by inducing either pancreatic inflammation or hyperplasia/dysplasia in nonhuman primates

Chronic Continuous Exenatide Infusion Does Not Cause Pancreatic Inflammation And Ductal Hyperplasia In Non-human Primates

In this study, we aimed to evaluate the effects of exenatide (EXE) treatment on exocrine pancreas of nonhuman primates. To this end, 52 baboons (Papio hamadryas) underwent partial pancreatectomy, followed by continuous infusion of EXE or saline (SAL) for 14 weeks. Histological analysis, immunohistochemistry, Computer Assisted Stereology Toolbox morphometry, and immunofluorescence staining were performed at baseline and after treatment. The EXE treatment did not induce pancreatitis, parenchymal or periductal inflammatory cell accumulation, ductal hyperplasia, or dysplastic lesions/pancreatic intraepithelial neoplasia. At study end, Ki-67-positive (proliferating) acinar cell number did not change, compared with baseline, in either group. Ki-67-positive ductal cells increased after EXE treatment (P = 0.04). However, the change in Ki-67-positive ductal cell number did not differ significantly between the EXE and SAL groups (P = 0.13). M-30-positive (apoptotic) acinar and ductal cell number did not change after SAL or EXE treatment. No changes in ductal density and volume were observed after EXE or SAL. Interestingly, by triple-immunofluorescence staining, we detected c-kit (a marker of cell transdifferentiation) positive ductal cells co-expressing insulin in ducts only in the EXE group at study end, suggesting that EXE may promote the differentiation of ductal cells toward a β-cell phenotype. In conclusion, 14 weeks of EXE treatment did not exert any negative effect on exocrine pancreas, by inducing either pancreatic inflammation or hyperplasia/dysplasia in nonhuman primates.1851139150Xu, G., Stoffers, D.A., Habener, J.F., Bonner-Weir, S., Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats (1999) Diabetes, 48, pp. 2270-2276Farilla, L., Hui, H., Bertolotto, C., Kang, E., Bulotta, A., Di Mario, U., Perfetti, R., Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats (2002) Endocrinology, 143, pp. 4397-4408Hui, H., Wright, C., Perfetti, R., Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells (2001) Diabetes, 50, pp. 785-796Fineman, M.S., Bicsak, T.A., Shen, L.Z., Taylor, K., Gaines, E., Varns, A., Kim, D., Baron, A.D., Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes (2003) Diabetes Care, 26, pp. 2370-2377Campbell, J.E., Drucker, D.J., Pharmacology, physiology, and mechanisms of incretin hormone action (2013) Cell Metab, 17, pp. 819-837Goldstein, B.J., Feinglos, M.N., Lunceford, J.K., Johnson, J., Williams-Herman, D.E., Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes (2007) Diabetes Care, 30, pp. 1979-1987. , Sitagliptin 036 Study GroupMeier, J.J., GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus (2012) Nat Rev Endocrinol, 8, pp. 728-742Meier, J.J., Nauck, M.A., Risk of pancreatitis in patients treated with incretin-based therapies (2014) Diabetologia, 57, pp. 1320-1324Forsmark, C.E., Billie, J., AGA institute technical review on acute pancreatitis (2007) Gastroenterology, 132, pp. 2022-2044Girman, C.J., Kou, T.D., Cai, B., Alexander, C.M., O'Neill, E.A., Williams-Herman, D.E., Katz, L., Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes (2010) Diabetes Obes Metab, 12, pp. 766-771Ben, Q., Xu, M., Ning, X., Liu, J., Hong, S., Huang, W., Zhang, H., Li, Z., Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies (2011) Eur J Cancer, 47, pp. 1928-1937Nauck, M.A., A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks (2013) Diabetes Care, 36, pp. 2126-2132Monami, M., Dicembrini, I., Nardini, C., Fiordelli, I., Mannucci, E., Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials (2014) Diabetes Res Clin Pract, 103, pp. 269-275Monami, M., Dicembrini, I., Mannucci, E., Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: A meta-analysis of randomized clinical trials (2014) Diabetes Obes Metab, 16, pp. 48-56Wenten, M., Gaebler, J.A., Hussein, M., Pelletier, E.M., Smith, D.B., Girase, P., Noel, R.A., Bloomgren, G.L., Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: A follow-up study (2012) Diabet Med, 29, pp. 1412-1418Garg, R., Chen, W., Pendergrass, M., Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: A retrospective observational pharmacy claims analysis (2010) Diabetes Care, 33, pp. 2349-2354Drucker, D.J., Sherman, S.I., Bergenstal, R.M., Buse, J.B., The safety of incretin-based therapies: Review of the scientific evidence (2011) J Clin Endocrinol Metab, 96, pp. 2027-2031Elashoff, M., Matveyenko, A.V., Gier, B., Elashoff, R., Butler, P.C., Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies (2011) Gastroenterology, 141, pp. 150-156Macconell, L., Brown, C., Gurney, K., Han, J., Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: Integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials (2012) Diabetes Metab Syndr Obes, 5, pp. 29-41White, W.B., Cannon, C.P., Heller, S.R., Nissen, S.E., Bergenstal, R.M., Bakris, G.L., Perez, A.T., Zannad, F., Alogliptin after acute coronary syndrome in patients with type 2 diabetes (2013) N Engl J Med, 369, pp. 1327-1335. , EXAMINE InvestigatorsScirica, B.M., Bhatt, D.L., Braunwald, E., Steg, P.G., Davidson, J., Hirshberg, B., Ohman, P., Raz, I., Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus (2013) N Engl J Med, 369, pp. 1317-1326. , SAVOR-TIMI 53 Steering Committee and InvestigatorsDrucker, D.J., Sherman, S.I., Gorelick, F.S., Bergenstal, R.M., Sherwin, R.S., Buse, J.B., Incretin-based therapies for the treatment of type 2 diabetes: Evaluation of the risks and benefits (2010) Diabetes Care, 33, pp. 428-433Butler, A.E., Campbell-Thompson, M., Gurlo, T., Dawson, D.W., Atkinson, M., Butler, P.C., Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors (2013) Diabetes, 62, pp. 2595-2604Harja, E., Lord, J., Skyler, J.S., An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology (2013) Diabetes Technol Ther, 15, pp. 609-618Bonner-Weir, S., In'T Veld, P.A., Weir, G.C., Reanalysis of study of pancreatic effects of incretin therapy: Methodological deficiencies (2014) Diabetes Obes Metab, 16, pp. 661-666Nachnani, J.S., Bulchandani, D.G., Nookala, A., Herndon, B., Molteni, A., Pandya, P., Taylor, R., Alba, L.M., Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas (2010) Diabetologia, 53, pp. 153-159Matveyenko, A.V., Dry, S., Cox, H.I., Moshtaghian, A., Gurlo, T., Galasso, R., Butler, A.E., Butler, P.C., Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: Interactions with metformin (2009) Diabetes, 58, pp. 1604-1615Gier, B., Matveyenko, A.V., Kirakossian, D., Dawson, D., Dry, S.M., Butler, P.C., Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras (G12D) mouse model (2012) Diabetes, 61, pp. 1250-1262Tatarkiewicz, K., Smith, P.A., Sablan, E.J., Polizzi, C.J., Aumann, D.E., Villescaz, C., Hargrove, D.M., Parkes, D.G., Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents (2010) Am J Physiol Endocrinol Metab, 299, pp. 1076-E1086Nyborg, N.C., Mølck, A.M., Madsen, L.W., Knudsen, L.B., The human GLP-1 analog liraglutide and the pancreas: Evidence for the absence of structural pancreatic changes in three species (2012) Diabetes, 61, pp. 1243-1249Vrang, N., Jelsing, J., Simonsen, L., Jensen, A.E., Thorup, I., Søeborg, H., Knudsen, L.B., The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: A quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis (2012) Am J Physiol Endocrinol Metab, 303, pp. 253-E264Chavez, A.O., Lopez-Alvarenga, J.C., Tejero, M.E., Triplitt, C., Bastarrachea, R.A., Sriwijitkamol, A., Tantiwong, P., Folli, F., Physiological and molecular determinants of insulin action in the baboon (2008) Diabetes, 57, pp. 899-908Guardado-Mendoza, R., Davalli, A.M., Chavez, A.O., Hubbard, G.B., Dick, E.J., Majluf-Cruz, A., Tene-Perez, C.E., Folli, F., Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons (2009) Proc Natl Acad Sci U S A, 106, pp. 13992-13997Guardado-Mendoza, R., Jimenez-Ceja, L., Majluf-Cruz, A., Kamath, S., Fiorentino, T.V., Casiraghi, F., Velazquez, A.O., Folli, F., Impact of obesity severity and duration on pancreatic α- And β-cells dynamics in normoglycemic non-human primates (2013) Int J Obes (Lond), 37, pp. 1071-1078Kamath, S., Chavez, A.O., Gastaldelli, A., Casiraghi, F., Halff, G.A., Abrahamian, G.A., Davalli, A.M., Folli, F., Coordinated defects in hepatic long chain fatty acid metabolism and triglyceride accumulation contribute to insulin resistance in non-human primates (2011) PLoS One, 6, p. 27617Casiraghi, F., Lertwattanarak, R., Luzi, L., Chavez, A.O., Davalli, A.M., Naegelin, T., Comuzzie, A.G., Folli, F., Energy expenditure evaluation in humans and non-human primates by SenseWear Armband: Validation of energy expenditure evaluation by SenseWear Armband by direct comparison with indirect calorimetry (2013) PLoS One, 8, p. 73651Bommineni, Y.R., Dick, E.J., Jr., Malapati, A.R., Owston, M.A., Hubbard, G.B., Natural pathology of the Baboon (Papio spp.) (2011) J Med Primatol, 40, pp. 142-155Guardado-Mendoza, R., Dick, E.J., Jr., Jimenez-Ceja, L.M., Davalli, A., Chavez, A.O., Folli, F., Hubbard, G.B., Spontaneous pathology of the baboon endocrine system (2009) J Med Primatol, 38, pp. 383-389Coelho, A.M., Jr., Carey, K.D., A social tethering system for nonhuman primates used in laboratory research (1990) Lab Anim Sci, 40, pp. 388-394McClure, H.M., Chandler, F.W., A survey of pancreatic lesions in nonhuman primates (1982) Vet Pathol Suppl, 7, pp. 193-209Mandarim-De-Lacerda, C.A., Stereological tools in biomedical research (2003) An Acad Bras Cienc, 75, pp. 469-486Quinn, A.R., Blanco, C.L., Perego, C., Finzi, G., La Rosa, S., Capella, C., Guardado-Mendoza, R., Folli, F., The ontogeny of the endocrine pancreas in the fetal/newborn baboon (2012) J Endocrinol, 214, pp. 289-299Hruban, R.H., Adsay, N.V., Albores-Saavedra, J., Compton, C., Garrett, E.S., Goodman, S.N., Kern, S.E., Offerhaus, G.J., Pancreatic intraepithelial neoplasia: A new nomenclature and classification system for pancreatic duct lesions (2001) Am J Surg Pathol, 25, pp. 579-586Hruban, R.H., Takaori, K., Klimstra, D.S., Adsay, N.V., Albores-Saavedra, J., Biankin, A.V., Biankin, S.A., Yonezawa, S., An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms (2004) Am J Surg Pathol, 28, pp. 977-987Bonner-Weir, S., Inada, A., Yatoh, S., Li, W.C., Aye, T., Toschi, E., Sharma, A., Transdifferentiation of pancreatic ductal cells to endocrine beta-cells (2008) Biochem Soc Trans, 36, pp. 353-356Egan, A.G., Blind, E., Dunder, K., De Graeff, P.A., Hummer, B.T., Bourcier, T., Rosebraugh, C., Pancreatic safety of incretin-based drugs: FDA and EMA assessment (2014) N Engl J Med, 370, pp. 794-797Butler, A.E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R.A., Butler, P.C., Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes (2003) Diabetes, 52, pp. 102-110Mezza, T., Muscogiuri, G., Sorice, G.P., Clemente, G., Hu, J., Pontecorvi, A., Holst, J.J., Kulkarni, R.N., Insulin resistance alters islet morphology in non-diabetic humans (2014) Diabetes, 63, pp. 994-1007Holland, T., Holland, C., Unbiased histological examinations in toxicological experiments (or, the informed leading the blinded examination) (2011) Toxicol Pathol, 39, pp. 711-71